LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

Information on the Total Number of Voting Rights and Shares

March 31, 2023 | Last Trade: US$4.57 0.03 0.66

Mont-Saint-Guibert (Belgium), March 31, 2023, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  •  Share capital: EUR 4,859,382.45 
  •  Total number of securities carrying voting rights: 28,286,985 (all ordinary shares) 
  •  Total number of voting rights (= denominator): 28,286,985 (all relating to ordinary shares)  
  •  Number of rights to subscribe to securities carrying voting rights not yet issued: 
    •  55 “2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 27,500 securities carrying voting rights (all ordinary shares); 
    •  100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);  
    •  430,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 430,500 securities carrying voting rights (all ordinary shares); and
    •  1,326,375 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,326,375 securities carrying voting rights (all ordinary shares); and
    •  700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).  

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313


Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page